Tolerogenic Nanovaccine for Prevention and Treatment of Autoimmune Encephalomyelitis

• DOI: 10.1002/adma.202202670
• Publication Date: 2022-10-08T08:55:48Z
• Authors: Jinwon Park; Quoc‐Viet Le; Yina Wu; Jaiwoo Lee; Yu‐Kyoung Oh
• Keywords: Myelin oligodendrocyte glycoprotein; CD80; Encephalomyelitis; CD86

Herein, a tolerogenic nanovaccine is developed and tested on an animal model of multiple sclerosis. The constructed to deliver the self-antigen, myelin oligodendrocyte glycoprotein (MOG) peptide, dexamethasone abatacept-modified polydopamine core nanoparticle (AbaLDPN-MOG). AbaLDPN-MOG can target dendritic cells undergo endocytosis followed by trafficking lysosomes. blocks interaction between CD80/CD86 CD28 in antigen-presenting T cells, leading decreased interferon gamma secretion. subcutaneous administration mice yields significant biodistribution lymph nodes and, experimental-autoimmune encephalomyelitis (EAE) mice, increases integrity basic sheath minimizes infiltration immune cells. EAE are treated with before or after injection autoantigen, MOG. Preimmunization MOG completely development clinical symptoms. Early treatment at three days also Notably, symptom-developed significantly alleviates symptoms, indicating that has therapeutic effects. Although AbaLDPN used for peptide delivery model, concept be widely applied prevention alleviation other autoimmune diseases.